Vaxxinity, Inc. VAXX


Sector:

Healthcare

Industry:

Biotechnology

Description:

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Recent Quarter:

2024-11-27

Upcoming Quarter:

2025-03-25

Annual Reports

Date2024-04-29
Revenue 0
Net Income -56,934
EPS -0.45
Basic Shares 126,509
Diluted Shares 126,508
Report Link
Date2023-03-27
Revenue 0
Net Income -75,210,000
EPS -0.6
Basic Shares 125,939,050
Diluted Shares 125,939,050
Report Link
Date2022-03-24
Revenue 66,000
Net Income -138,015,000
EPS -1.1
Basic Shares 125,392,226
Diluted Shares 125,392,226
Report Link
Date2020-12-31
Revenue 557,000
Net Income -35,377,000
EPS -0.28
Basic Shares 125,453,178
Diluted Shares 125,453,178
Report Link
Date2019-12-31
Revenue 0
Net Income -14,219,000
EPS -0.11
Basic Shares 125,453,178
Diluted Shares 125,453,178
Report Link

Annual Ratios

Date2023-12-31
PE -1.89
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -2.34
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -5.10
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -58.69
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-12-31
PE -146.02
Dividend Yield 0.00
Payout Ratio: 0.000%

Quarterly Reports

Date2024-04-29
Revenue 0
Net Income -11,392,000
EPS -0.0895
Basic Shares 127,218,000
Diluted Shares 127,218,000
Report Link
Date2023-11-08
Revenue 0
Net Income -13,145,000
EPS -0.1
Basic Shares 126,736,784
Diluted Shares 126,736,784
Report Link
Date2023-08-09
Revenue 0
Net Income -13,977,000
EPS -0.11
Basic Shares 126,481,497
Diluted Shares 126,481,497
Report Link
Date2023-05-09
Revenue 0
Net Income -18,409,000
EPS -0.15
Basic Shares 126,061,273
Diluted Shares 126,061,273
Report Link
Date2023-03-27
Revenue 0
Net Income -20,472,000
EPS -0.16
Basic Shares 126,056,241
Diluted Shares 126,056,241
Report Link
Date2022-11-10
Revenue 0
Net Income -19,252,000
EPS -0.15
Basic Shares 126,036,865
Diluted Shares 126,036,865
Report Link
Date2022-08-11
Revenue 0
Net Income -17,280,000
EPS -0.14
Basic Shares 125,948,595
Diluted Shares 125,948,595
Report Link
Date2022-05-09
Revenue 0
Net Income -18,262,000
EPS -0.15
Basic Shares 125,709,000
Diluted Shares 125,709,613
Report Link
Date2022-03-24
Revenue -1,000
Net Income -48,191,000
EPS -0.38
Basic Shares 125,392,226
Diluted Shares 125,392,226
Report Link
Date2021-12-23
Revenue 50,000
Net Income -30,389,000
EPS -0.24
Basic Shares 125,394,115
Diluted Shares 125,453,178
Report Link
Date2021-06-30
Revenue 0
Net Income -26,910,000
EPS -0.22
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2021-03-31
Revenue 17,000
Net Income -32,021,000
EPS -0.26
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-12-31
Revenue 0
Net Income -12,719,000
EPS -0.1
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-09-30
Revenue 117,000
Net Income -16,465,000
EPS -0.13
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-06-30
Revenue 440,000
Net Income -7,061,000
EPS -0.0566
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-03-31
Revenue 0
Net Income -3,711
EPS -0.11
Basic Shares 34,927
Diluted Shares 34,927
Report Link

Quarterly Ratios

Date2023-12-31
PE -2.37
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-09-30
PE -3.30
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-06-30
PE -5.70
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-03-31
PE -3.89
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -2.16
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-09-30
PE -3.24
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-06-30
PE -2.86
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-03-31
PE -7.40
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -3.65
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-09-30
PE -17.07
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-06-30
PE -19.18
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-03-31
PE -16.12
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -40.58
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-09-30
PE -31.35
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-06-30
PE -73.10
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-03-31
PE -38.94
Dividend Yield 0.00
Payout Ratio: 0.000%

RSI:

44.70

Price:

$0.00

Market Cap:

12,678

EPS TTM:

-0.45

PE Ratio:

-0.00

PEPSG:

NaN

Fwd PE:

NaN

Volume:

21,762

2 Year Price Change

0.000

Index 2 Year Price Change

1.513

5 Year Price Change

No Price 5 Years Ago

Index 5 Year Price Change

1.906

PESPG: Growth Rate of EPS projected to next quarter and 6 months trailing. Lower is better to help calculate nexts quarters PE Ratio today. Diluted shares effects the EPS reported and makes calculation show as extremely poor expected growth.

Revenue

Net Income

EPS

Shares

News

Press Releases

Notable Earnings

Please select an option: